NR1H4 and metabolic dysfunction-associated steatohepatitis: In addition, INT-767 was also evaluated for the treatment of non-alcoholic steatohepatitis (NASH) and intestinal ischemia reperfusion injury (IRI) because of its function as a dual FXR/Takeda G protein-coupled receptor 5 (TGR5) agonist (Anfuso et al., 2020).